Enlarged and prominent nucleoli may be indicative of MYCN amplification: A study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index

Cancer

Volumn 103, Issue 1, 2005, Pages 174-180

  Kobayashi, Chie ^a   Monforte Munoz, Hector L ^a   Gerbing, Robert B ^b   Stram, Daniel O ^c   Matthay, Katherine K ^d   Lukens, John N ^e   Seeger, Robert C ^a   Shimada, Hiroyuki ^a,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Clinical characteristics; Cytology; Histology; International Neuroblastoma Pathology Classification; Morphometry; MYCN status; Neuroblastoma; Nucleoli; Prognosis

Indexed keywords

MYCN PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CHILD; CYTOLOGY; GENE; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; INTERNATIONAL NEUROBLASTOMA PATHOLOGY CLASSIFICATION; MAJOR CLINICAL STUDY; MITOSIS; MORPHOMETRICS; MULTIMODALITY CANCER THERAPY; MYCN GENE; NEUROBLASTOMA; NUCLEOLUS; PRIORITY JOURNAL;

CELL NUCLEOLUS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 10844284701     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20717     Document Type: Article

References (23)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology (4th edition). Philadelphia: Lippincott Williams & Wilkins, 2002:865-937.
2. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405-413.
3. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi W, Roald B. Terminology and morphologic criteria of neuroblastic tumors. Recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349-363.
4. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. A report from the Children's Cancer Group. Cancer. 2001;92:2451-2461.
5. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364-372.
6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science. 1984;224:1121-1124.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111-1116.
8. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastoma by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995;19:1470-1476.
9. Schwab M. MYCN amplification in neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier, 2000:75-83.
10. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of Stage I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group Study. J Clin Oncol. 2000;18:18-26.
11. Matthay KK, Perez CA, Seeger RC, et al. Successful treatment of Stage III neuroblastoma based on prospective biological staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256-1264.
12. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determined prognosis in infants with Stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260-1268.
13. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
14. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. A report from the Children's Cancer Group. Cancer. 2001;92:2699-2708.
15. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer. 1971;27:374-378.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Ambros IM, Hata J, Joshi W, et al. Morphologic features of neuroblastoma (Schwannian atroma-poor tumors) in clinically favorable and unfavorable groups. Cancer. 2002;94:1574-1583
18. Tornoczky T, Kalman E, Kajtar P, et al. Large cell neuroblastoma - a distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer. 2004;100:390-397.
19. Matsumoto T, Terasaki T, Mukai K, et al. Relation between nucleolar size and growth characteristics in small cell lung cancer cell lines. Jpn J Cancer Res. 1991;82:820-828.
20. Pession A, Trere D, Perri P, et al. N-myc amplification and cell proliferation rate in human neuroblastoma. J Pathol. 1997;183:339-344.
21. Derenzini M, Trere D, Pession A, Govoni M, Sirri V, Chieco P. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol. 2000;191:181-186.
22. Arabi A, Rustum C, Hallberg E, Wright AP. Accumulation of c-Myc and proteasome at the nucleoli of cells containing elevated c-Myc protein levels. J Cell Sci. 2003;116:1707-1717.
23. Bond VC, Wold B. Nucleolar localization of myc transcripts. Mol Cell Biol. 1993;13:3221-3230.